FDA Approves MYCOPHENOLIC ACID — Apotex Corp

On August 19, 2014, Apotex Corp received FDA approval for Mycophenolic Acid, a generic version of Mycophenolate Sodium tablets, signaling a shift in the market dynamics for immunosuppressant medications typically utilized by transplant and autoimmune disease patients. The entry of this authorized generic is expected to intensify competitive pricing pressures and reduce treatment costs across the affected pharmaceutical sectors.